Related references
Note: Only part of the references are listed.Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer
Maryann Kwa et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Checkpoint Blockade in Lung Cancer and Mesothelioma
Lysanne A. Lievense et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Novel insights into mesothelioma biology and implications for therapy
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2017)
Low dose cyclophosphamide: Mechanisms of T cell modulation
Mutsa Tatenda Madondo et al.
CANCER TREATMENT REVIEWS (2016)
Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Floris Dammeijer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg et al.
NATURE REVIEWS CANCER (2016)
Metastatic Melanoma - A Review of Current and Future Treatment Options
Emanual Maverakis et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
Saskia J. A. M. Santegoets et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Postoperative Regulatory T-Cells and Natural Killer Cells in Stage I Nonsmall Cell Lung Cancer Underwent Video-assisted Thoracoscopic Lobectomy or Thoracotomy
Sai Zhang et al.
CHINESE MEDICAL JOURNAL (2015)
Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)
Koji Kurose et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
Michal Podrazil et al.
ONCOTARGET (2015)
Nivolumab in melanoma: latest evidence and clinical potential
Douglas B. Johnson et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Nivolumab in NSCLC: latest evidence and clinical potential
Raghav Sundar et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic
Franck Housseau et al.
ONCOIMMUNOLOGY (2015)
Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model
Junjie Wu et al.
CANCER LETTERS (2014)
Immunomodulation in cancer
Joost P. J. J. Hegmans et al.
CURRENT OPINION IN PHARMACOLOGY (2014)
Changes of CD4+CD25+FOXP3+and CD8+CD28-regulatory T cells in non-small cell lung cancer patients undergoing surgery
Cheng Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
Homeostatic control of regulatory T cell diversity
Adrian Liston et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies
Melanie J. McCoy et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Malignant Pleural Mesothelioma Update on Treatment Options with a Focus on Novel Therapies
Andrew R. Haas et al.
CLINICS IN CHEST MEDICINE (2013)
Human CD4+CD25+Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response
Daniel Heylmann et al.
PLOS ONE (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Expanding roles for CD4T cells and their subpopulations in tumor immunity and therapy
Mark J. Dobrzanski
FRONTIERS IN ONCOLOGY (2013)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Optimal Population of FoxP3+ T Cells in Tumors Requires an Antigen Priming-Dependent Trafficking Receptor Switch
Chuanwu Wang et al.
PLOS ONE (2012)
The Role of Regulatory T Cells in Mesothelioma
Demelza J. Ireland et al.
CANCER MICROENVIRONMENT (2012)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
Tom Treasure et al.
LANCET ONCOLOGY (2011)
Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low-dose IL-2
J. Bjoern et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2011)
Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
Joost P. Hegmans et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Joris D. Veltman et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
Different Proliferative Potential and Migratory Characteristics of Human CD4+ Regulatory T Cells That Express either CD45RA or CD45R0
Nicola J. Booth et al.
JOURNAL OF IMMUNOLOGY (2010)
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
Makoto Miyara et al.
IMMUNITY (2009)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration
Laura Bracci et al.
CLINICAL CANCER RESEARCH (2007)
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
J. P. J. J. Hegmans et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Oestradiol potentiates the suppressive function of human CD4+ CD25+ regulatory T cells by promoting their proliferation
GA Prieto et al.
IMMUNOLOGY (2006)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model
P Matar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Share Paper
